Pharma Business - February 28, 2018
MedImmune to create stand-alone company
AstraZeneca’s global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio. The new company will focus on developing medicines for severe autoimmune diseases by targeting the underlying causes of each disease. MedImmune will contribute three clinical and three pre-clinical […]
Clinical Trials - September 11, 2017
Celgene and AstraZeneca report update on clinical trial programme
MedImmune, AstraZeneca’s global biologics R&D arm, have been informed by partner Celgene that the US Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION programme. The trials are testing Imfinzi (durvalumab), an anti-PD-L1 agent, in combination with immunomodulatory agents, with or […]
Profiles in Pharma - July 1, 2017
Embracing diversity – for the sake of true innovation
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief in the need for diversity to truly bring forth innovation. A view that is also deeply incorporated in her job as Head of MedImmune. Editor’s note: In 2019 Bahika Jallal left MedImmune and became the […]
Agreement - March 3, 2017
MedImmune forms development alliance with Sanofi Pasteur
Medimmune and Sanofi Pasteur have announced an agreement to develop and commercialise MEDI8897, a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV,) jointly. MEDI8897 is currently in a Phase IIb clinical trial in pre-term infants who are ineligible for Synagis, the current standard of care medicine, […]
Agreement - November 28, 2016
MedImmune, Abpro in agreement
MedImmune and Abpro have entered into a collaborative agreement to advance the development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF). The agreement is structured as a spin out, benefiting from both companies’ scientific expertise and Abpro’s day-to-day leadership as it oversees the new company, AbMed. Several potential therapeutic […]
Drug Development Pharma - April 22, 2016
AZ launches integrated genomics approach
AstraZeneca and its global biologics research and development arm, MedImmune, has announced an integrated genomics initiative to transform drug discovery and development across its entire research and development pipeline. The initiative involves for example a new collaboration with the Institute for Molecular Medicine in Finland. The initiative includes new collaborations with Human Longevity, US, the Wellcome […]
